Avis Budget is set up for the short squeeze of the year and can 10x from here. Two hedge funds own a combined 108%, holding 71% of the float plus more through derivatives, while 54% of the float is sold short. It will eventually fall 90%, but likely rises 2-5x first; trading it is risky, with put premiums ultra high. x.com  x.com 

Twist Bioscience is squeeze material, with a small float and 19% short interest. It is a former IBD sector leader and a rare biotech with revenue. x.com 

C3is trades far below its cash: about $48M on the books against a float of roughly 1.5-2 million shares implies $24-32 a share, yet the stock is near $1.5, and the company is now profitable. It was a dilution machine while acquiring its fleet, but the story looks to be changing. Short interest is 55%, cost to borrow 146%, few shares remain to short, and institutional ownership rose. About 450,000-500,000 warrants at $1.51 and $2.44 remain, making $2.44 the next target. x.com  x.com  x.com  x.com  … Show more

Jaguar Health is one to avoid despite its premarket jump, given its delisting risk. The stock is hard to borrow and rates 9/10 as a squeeze candidate. The company's announcement of a special stock dividend is a plausible driver of the speculative interest. x.com 

Rising Dragon Acquisition, Yunji and Tenon Medical are shorting opportunities because nothing but low float and momentum is holding them up. All three are top gainers with no news or filings. Premarket traders build momentum, retail chases the stock higher, and early buyers then take profits, reversing the move. Shorting no-news top gainers has an excellent success rate over time. x.com 

Sadot Group is a high-risk, high-reward squeeze candidate with room to run to $40 or more. It has only about 650,000 shares of float, rose 42% on the day, was halted up and shows a daily squeeze signal; it just needs more volume. A break above $33 could set it off. x.com  x.com 

Lumentum is set up for a short squeeze at new all-time highs, given its small float and 16% short interest. x.com 

Wendy's, Xerox and Icahn Enterprises are set up for a short squeeze. They are the only stocks with over 30% short interest that pay dividends above 7%, so shorts pay heavily to stay short and lose more if prices rise. All three are in Stage 2 uptrends, and Wendy's and Xerox are retesting recent high-volume breakouts. A short-covering summer could start if the market breaks higher out of its consolidation. x.com 

China SXT Pharmaceuticals is a short-squeeze candidate: short interest exceeds 20%, institutional ownership exceeds 100%, no shares are left to borrow and the cost to borrow is over 500%. It has the same setup as other low-float, high-short-interest plays; after coiling all day, a pop on incoming volume is only a matter of time because shorts are trapped. x.com  x.com